Medicine and Dentistry
Hepatocellular Carcinoma
100%
Yttrium 90
98%
Radioembolization
96%
Neoplasm
72%
Microsphere
43%
Diseases
43%
Transcatheter Arterial Chemoembolization
42%
Malignant Neoplasm
40%
Metastatic Carcinoma
39%
Oncology
34%
Cancer
34%
Pancreas Cancer
30%
Liver Metastasis
29%
Overall Survival
29%
Colorectal Carcinoma
26%
Liver Tumor
24%
Colon Carcinoma
24%
Rectum Cancer
21%
Radiation Therapy
20%
Adjuvant Therapy
19%
Gemcitabine
18%
Bevacizumab
17%
Necrosis
16%
Adenocarcinoma
15%
Chemoradiotherapy
14%
Progression Free Survival
14%
Systemic Therapy
14%
Metastatic Colorectal Cancer
13%
Perfusion Weighted Imaging
13%
Liver Cancer
12%
Clinical Trial
12%
Recurrent Disease
12%
Abdominal Cancer
11%
Magnetic Resonance Imaging
11%
Phase II Trials
11%
COVID-19
10%
Anus Carcinoma
10%
Quality of Life
10%
Oxaliplatin
10%
Cholangiocarcinoma
9%
Esophageal Cancer
9%
Gastroesophageal Junction
9%
Arterial Embolization
9%
Esophagus
9%
Diffusion MRI
9%
Arm
8%
Response Evaluation Criteria in Solid Tumors
8%
Alpha-Fetoprotein
8%
Neoadjuvant Therapy
8%
Multivariate Analysis
8%
Keyphrases
Hepatocellular Carcinoma
92%
Radioembolization
62%
Yttrium-90 Radioembolization
54%
Colorectal Cancer
52%
Yttrium-90 Microspheres
37%
Chemoembolization
36%
Chemotherapy
31%
Tumor
29%
NCCN Guidelines
26%
Metastatic Colorectal Cancer (mCRC)
25%
Metastatic Disease
25%
Colon Cancer
24%
Phase II Study
23%
Bevacizumab
23%
Oncology
23%
Overall Survival
22%
Gemcitabine
22%
Intra-arterial
22%
5-fluorouracil (5-FU)
21%
Yttrium-90
21%
Phase II Trial
21%
Adjuvant Therapy
19%
Confidence Interval
19%
Gastric Cancer
19%
Liver Metastasis
18%
Resectable Pancreatic Cancer
18%
Necrosis
17%
Radiotherapy
16%
Tumor Response
16%
Systemic Therapy
16%
Oxaliplatin
16%
Resection
16%
Liver Tumor
15%
Clinical Trials
15%
Locoregional Therapy
15%
Clinical Practice Guidelines
15%
Transcatheter
14%
European Association for the Study of the Liver
14%
Response Rate
14%
Time to Progression
14%
Gastroesophageal Junction Cancer
13%
Transcatheter Arterial Chemoembolization
13%
World Health Organization
13%
Liver
13%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Leucovorin
12%
Partial Response
12%
Esophageal Cancer
12%
Progression-free Survival
11%
Docetaxel
11%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
61%
Yttrium 90
59%
Neoplasm
42%
Malignant Neoplasm
42%
Diseases
39%
Chemotherapy
28%
Microsphere
28%
Overall Survival
26%
Colorectal Carcinoma
22%
Pancreas Cancer
21%
Bevacizumab
19%
Fluorouracil
18%
Gemcitabine
17%
Adenocarcinoma
17%
Chemoradiation Therapy
16%
Solid Malignant Neoplasm
16%
Colon Carcinoma
16%
Liver Metastasis
16%
Progression Free Survival
16%
Metastatic Colorectal Cancer
15%
Phase II Trials
14%
Oxaliplatin
12%
Folinic Acid
12%
Necrosis
11%
Docetaxel
11%
Abdominal Cancer
11%
Sorafenib
11%
Clinical Trial
10%
Cisplatin
8%
Pharmacokinetics
8%
Rectum Cancer
8%
Disease Exacerbation
8%
Adverse Event
7%
Pancreas Adenocarcinoma
7%
Placebo
7%
Immunotherapy
7%
Liver Cancer
7%
Capecitabine
6%
Irinotecan
6%
Paclitaxel
6%
Portal Vein Thrombosis
6%
Squamous Cell Carcinoma
5%
Biological Marker
5%
Neutropenia
5%
Bilirubin
5%
Liver Disease
5%
Tolerability
5%
Maximum Tolerated Dose
5%
Trastuzumab
5%
Comorbidity
5%